Multicenter phase II study of iodine-131 tositumomab for chemotherapy- relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas Academic Article uri icon

Overview

MeSH Major

  • Antibodies, Monoclonal
  • Immunoconjugates
  • Lymphoma, B-Cell
  • Lymphoma, Non-Hodgkin
  • Radioimmunotherapy

abstract

  • Iodine-131 tositumomab produced a high overall response rate, and approximately one third of patients had a CR despite having chemotherapy-relapsed or refractory low-grade or transformed low-grade NHL.

publication date

  • March 2000

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed ID

  • 10715303

Additional Document Info

start page

  • 1316

end page

  • 23

volume

  • 18

number

  • 6